文献速递前列腺癌膀胱癌与上尿路尿路上皮癌肾癌与肾肿瘤

欧洲泌尿系统癌症死亡率趋势:1980-2017年及2025年预测

Mortality Trends from Urologic Cancers in Europe over the Period 1980-2017 and a Projection to 2025.
PubMed 文献 · Eur Urol Oncol · 2021-06-05

该研究基于世界卫生组织数据库,分析36个欧洲国家1980-2017年前列腺癌、睾丸癌、膀胱癌和肾癌的年龄标准化死亡率,并用joinpoint回归预测2025年。结果显示前列腺癌、睾丸癌和膀胱癌死亡率在多数欧洲国家下降,但肾癌死亡率男性略升、女性稳定;东欧趋势较差。

要点

  • 欧盟前列腺癌死亡率2015年为10.3/10万,预测2025年降至8.9/10万。
  • 欧盟睾丸癌死亡率2015年全年龄0.3/10万,20-44岁0.6/10万。
  • 膀胱癌死亡率2015年欧盟男性5.1/10万、女性1.1/10万。

核心结论

  • 多数欧洲国家前列腺癌、睾丸癌和膀胱癌死亡率下降,但肾癌未下降。
  • 东欧国家死亡率趋势较不乐观。

研究设计与样本

  • 基于世界卫生组织官方数据库的时间趋势分析,覆盖36个欧洲国家1980-2017年。
  • 计算年龄标准化(世界人口)死亡率,并对选定主要国家进行joinpoint回归分析。
  • 使用对数泊松计数数据joinpoint回归模型预测2025年死亡数和率。

主要发现

  • 欧盟前列腺癌死亡率2015年为10.3/10万,预测2025年为8.9/10万。
  • 东欧前列腺癌死亡率趋势较不乐观,但起点较低。
  • 多数国家睾丸癌死亡率下降,但北欧和西欧在达到极低率后趋于平稳。
  • 欧盟睾丸癌死亡率2015年全年龄为0.3/10万,20-44岁为0.6/10万。
  • 中欧和东欧膀胱癌死亡率趋势较北欧和西欧差;欧盟2015年男性5.1/10万、女性1.1/10万。

临床怎么用

  • 监测欧洲泌尿系统癌症死亡率趋势可为医疗资源配置和癌症控制策略提供依据。
  • 东欧地区需加强前列腺癌、膀胱癌和肾癌的防治措施。

局限性

  • 原文未明确报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patterns and trends in urologic cancer mortality still show geographical differences across Europe. OBJECTIVE: To monitor mortality trends from urologic cancers, including prostate, testis, bladder, and kidney cancers, in Europe. DESIGN, SETTING, AND PARTICIPANTS: We carried out a time-trend analysis for 36 European countries using the official World Health Organization database. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We extracted the number of deaths and population data over the 1980-2017 period, and calculated age-standardised (world population) mortality rates for each cancer considered, sex, country, and the European Union (EU) as a whole, at all ages; at ages 35-64 yr for prostate, bladder, and kidney cancers; and at ages 20-44 yr for testicular cancer. For selected major countries, we carried out a joinpoint regression analysis to identify significant changes in trends. We also predicted the number of deaths and rates for 2025, using a logarithmic Poisson count data joinpoint regression model. RESULTS AND LIMITATIONS: Prostate cancer mortality in the EU decreased over recent years, reaching a rate of 10.3/100 000 in 2015 and a projected rate of 8.9/100 000 in 2025. Less favourable trends were observed in eastern Europe, though starting from relatively low rates. Testicular cancer mortality declined over time in most countries, however levelling off in northern and western countries, after reaching very low rates. EU testicular cancer mortality rate in 2015 was 0.3/100 000 at all ages and 0.6/100 000 at ages 20-44 yr. Bladder cancer mortality trends were less favourable in central and eastern countries compared to northern and western ones. The EU rates in 2015 were 5.1/100 000 men and 1.1/100 000 women. Kidney cancer mortality showed less favourable trends, with a slight increase in men and stable rates in women over the past decade in the EU. CONCLUSIONS: Mortality from prostate, testis, and bladder cancers, but not from kidney cancer, declined in most European countries, with less favourable trends in most eastern countries. PATIENT SUMMARY: Over the past four decades, mortality from prostate, testis, and bladder cancers, but not from kidney cancer, declined in most European countries. Prostate cancer mortality rates remain lower in Mediterranean countries than in northern and central Europe. Rates for all urologic cancers remain higher in central and eastern Europe.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Bertuccio P, Santucci C, Carioli G, et al. Mortality Trends from Urologic Cancers in Europe over the Period 1980-2017 and a Projection to 2025. Eur Urol Oncol. 2021. PMID: 34103280. doi:10.1016/j.euo.2021.05.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。